Complications of chronic kidney disease: Anemia, mineral metabolism, and cardiovascular disease

Medical Clinics of North America

Volumn 89, Issue 3, 2005, Pages 549-561

  Pendse, Shona ^a   Singh, Ajay K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ALUMINUM PHOSPHATE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM PHOSPHATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARICALCITOL; RECOMBINANT ERYTHROPOIETIN; SEVELAMER; VITAMIN D;

ANEMIA; ARTERY CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIALYSIS; DISEASE ASSOCIATION; DRUG HALF LIFE; DYSLIPIDEMIA; HEART FAILURE; HUMAN; HYPERCALCEMIA; HYPERTENSION; KIDNEY FAILURE; MINERAL METABOLISM; MORTALITY; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM; VITAMIN SUPPLEMENTATION;

EID: 14744304006     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2004.12.004     Document Type: Review

References (105)

1. US Department of Health and Human Services Office of Disease Prevention and Health Promotion-Healthy People 2010 Nasnewsletter 15 2000 3
2. J. Coresh Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey Am J Kidney Dis 41 2003 1 12
3. C.A. Jones Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey Am J Kidney Dis 32 1998 992 999
4. Kidney Disease Outcome Quality Initiative K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2 Suppl 2 2002 S1 S246
5. R.J. Hogg National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification Pediatrics 111 6 Pt 1 2003 1416 1421
6. A.S. Levey National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 139 2003 137 147
7. N.S. Anavekar Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction N Engl J Med 351 2004 1285 1295
8. A.S. Go Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
9. L. Agodoa United States Renal Data System (USRDS) Nefrologia 20 Suppl 5 2000 13 16
10. L. Cooper USRDS. 2001 Annual data report Nephrol News Issues 15 2001 31
11. J.L. Xue Anemia treatment in the pre-ESRD period and associated mortality in elderly patients Am J Kidney Dis 40 2002 1153 1161
12. D.C. Wheeler, J.N. Townend, and M.J. Landray Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study Kidney Int Suppl 84 2003 S201 S203
13. J. Portoles The beneficial effects of intervention in early renal disease Nephrol Dial Transplant 16 Suppl 2 2001 12 15
14. J.F. Mann Cardiovascular risk in patients with mild renal insufficiency Kidney Int Suppl 84 2003 S192 S196
15. J.F. Mann Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors Am J Cardiovasc Drugs 2 2002 157 162
16. A. Levin Prevalence of cardiovascular damage in early renal disease Nephrol Dial Transplant 16 Suppl 2 2001 7 11
17. G.M. Chertow, S.L. Normand, and B.J. McNeil Renalism: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency J Am Soc Nephrol 15 2004 2462 2468
18. Consensus Development Conference Panel Morbidity and mortality of renal dialysis: an NIH consensus conference statement Ann Intern Med 121 1994 62 70
19. M. Rao The Study of Treatment for Renal Insufficiency: Data and Evaluation (STRIDE), a national registry of chronic kidney disease Semin Dial 15 2002 366 369
20. R. Dikow Strategies to decrease cardiovascular mortality in patients with end-stage renal disease Kidney Int Suppl 80 2002 5 10
21. R. Dikow, and E. Ritz Cardiovascular complications in the diabetic patient with renal disease: an update in 2003 Nephrol Dial Transplant 18 2003 1993 1998
22. F. Madore Uremia-related metabolic cardiac risk factors in chronic kidney disease Semin Dial 16 2003 148 156
23. E. Ritz, R. Dikow, and L.M. Ruilope Renal dysfunction as a cardiovascular risk factor Curr Hypertens Rep 4 2002 365 368
24. K. Uhlig, A.S. Levey, and M.J. Sarnak Traditional cardiac risk factors in individuals with chronic kidney disease Semin Dial 16 2003 118 127
25. L.F. Fried Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals J Am Coll Cardiol 41 2003 1364 1372
26. C. Zoccali Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention Nephrol Dial Transplant 17 Suppl 11 2002 50 54
27. J.M. Gomez, and F. Carrera What should the optimal target hemoglobin be? Kidney Int Suppl 80 2002 39 43
28. A. Levin Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin Am J Kidney Dis 34 1999 125 134
29. A. Levin Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention Am J Kidney Dis 27 1996 347 354
30. R.N. Foley Clinical and echocardiographic disease in patients starting end-stage renal disease therapy Kidney Int 47 1995 186 192
31. A.J. Collins Cardiovascular disease in end-stage renal disease patients Am J Kidney Dis 38 4 Suppl 1 2001 S26 S29
32. J. Fink Use of erythropoietin before the initiation of dialysis and its impact on mortality Am J Kidney Dis 37 2001 348 355
33. J. Portoles Cardiovascular effects of recombinant human erythropoietin in predialysis patients Am J Kidney Dis 29 1997 541 548
34. T. Hayashi Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure Am J Kidney Dis 35 2000 250 256
35. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000 Am J Kidney Dis 37 1 Suppl 1 2001 S182 S238
36. L. Stevens, C. Stigant, and A. Levin Should hemoglobin be normalized in patients with chronic kidney disease? Semin Dial 15 2002 8 13
37. National Kidney Foundation-Dialysis Outcomes Quality Initiative NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure Am J Kidney Dis 30 4 Suppl 3 1997 S192 S240
38. J.S. Cameron European best practice guidelines for the management of anaemia in patients with chronic renal failure Nephrol Dial Transplant 14 Suppl 2 1999 61 65
39. C. Jacobs European best practice guidelines 5: target haemoglobin Nephrol Dial Transplant 15 Suppl 4 2000 15 19
40. A. Besarab The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590
41. F. Valderrabano PRE-dialysis survey on anaemia management Nephrol Dial Transplant 18 2003 89 100
42. G.T. Obrador, and B.J. Pereira Systemic complications of chronic kidney disease: pinpointing clinical manifestations and best management Postgrad Med 111 2002 115 122
43. G.T. Obrador Trends in anemia at initiation of dialysis in the United States Kidney Int 60 2001 1875 1884
44. G.T. Obrador Pre-end-stage renal disease care in the United States: a state of disrepair J Am Soc Nephrol 9 12 Suppl 1998 S44 S54
45. M.N. Fukuda Survival of recombinant erythropoietin in the circulation: the role of carbohydrates Blood 73 1989 84 89
46. A.R. Nissenson Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients Am J Kidney Dis 40 2002 110 118
47. A.R. Nissenson Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease Am J Kidney Dis 38 2001 1390 1397
48. A.R. Nissenson Dosing darbepoetin alfa continued Am J Kidney Dis 41 2003 1334 1335
49. A.R. Nissenson Dosing darbepoetin alfa Am J Kidney Dis 40 2002 872
50. I.C. Macdougall, J. Matcham, and S.J. Gray Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis Nephrol Dial Transplant 18 2003 576 581
51. I.C. Macdougall Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients J Am Soc Nephrol 10 1999 2392 2395
52. F. Locatelli Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency Kidney Int 60 2001 741 747
53. Y. Vanrenterghem Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients Kidney Int 62 2002 2167 2175
54. E. Slatopolsky On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake Kidney Int 2 1972 147 151
55. E. Slatopolsky, and N.S. Bricker The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease Kidney Int 4 1973 141 145
56. R.S. Goldsmith Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. 3. Evaluation of parathyroid suppressibility J Clin Invest 52 1973 173 180
57. E. Slatopolsky Hyperphosphatemia Clin Nephrol 7 1977 138 146
58. E. Slatopolsky The role of phosphate and other factors on the pathogenesis of renal osteodystrophy Adv Exp Med Biol 81 1977 467 475
59. W.E. Rutherford Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog J Clin Invest 60 1977 332 341
60. E. Rutherford An evaluation of a new and effective phosphorus binding agent Trans Am Soc Artif Intern Organs 19 1973 446 449
61. E. Slatopolsky Alternative phosphate binders in dialysis patients: calcium carbonate Semin Nephrol 6 4 Suppl 1 1986 35 41
62. M.L. Mai Calcium acetate, an effective phosphorus binder in patients with renal failure Kidney Int 36 1989 690 695
63. G. Hercz Use of calcium carbonate as a phosphate binder in dialysis patients Miner Electrolyte Metab 12 1986 314 319
64. A.J. Smith Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis Am J Nephrol 6 1986 275 283
65. H.H. Malluche, and M.C. Monier-Faugere Risk of adynamic bone disease in dialyzed patients Kidney Int Suppl 38 1992 S62 S67
66. H.H. Malluche, and M.C. Faugere Aluminum-related bone disease Blood Purif 6 1988 1 15
67. H.H. Malluche, and H. Mawad Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions Nephrol Dial Transplant 17 2002 1170 1175
68. J. Braun Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients Am J Kidney Dis 27 1996 394 401
69. G.A. Block Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study Am J Kidney Dis 31 1998 607 617
70. W.G. Goodman Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis N Engl J Med 342 2000 1478 1483
71. E.A. Slatopolsky, S.K. Burke, and M.A. Dillon RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group Kidney Int 55 1999 299 307
72. R. Ramsdell Renagel: a new and different phosphate binder Anna J 26 1999 346 347
73. G.M. Chertow Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients Nephrol Dial Transplant 14 1999 2907 2914
74. A.J. Bleyer A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients Am J Kidney Dis 33 1999 694 701
75. G.M. Chertow A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium: strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients Clin Nephrol 51 1999 18 26
76. D.I. Goldberg Effect of RenaGel, a non-absorbed, calcium- and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients Nephrol Dial Transplant 13 1998 2303 2310
77. S.K. Burke, E.A. Slatopolsky, and D.I. Goldberg RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers Nephrol Dial Transplant 12 1997 1640 1644
78. B.M. Wilkes Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients Clin Nephrol 50 1998 381 386
79. A.J. Collins Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients Clin Nephrol 54 2000 334 341
80. E. Slatopolsky, J. Finch, and A. Brown New vitamin D analogs Kidney Int Suppl 85 2003 S83 S87
81. E. Slatopolsky, A. Dusso, and A. Brown New analogs of vitamin D3 Kidney Int Suppl 73 1999 S46 S51
82. T. Sugimoto, C. Ritter, and E. Slatopolsky Effect of 1,25- dihydroxyvitamin D3 on phospholipid metabolism in cultured bovine parathyroid cells Endocrinology 122 1988 2387 2392
83. T. Sugimoto, C. Ritter, and I. Ried Effect of 1,25-dihydroxyvitamin D3 on cytosolic calcium in dispersed parathyroid cells Kidney Int 33 1988 850 854
84. T. Akizawa, M. Suzuki, and T. Akiba Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study Nephrol Dial Transplant 17 Suppl 10 2002 28 36
85. L.V. Avioli, S. Birge, and S.W. Lee The metabolic fate of vitamin D3-3H in chronic renal failure J Clin Invest 47 1968 2239 2252
86. K. Olgaard, D. Finco, and J. Schwartz Effect of 24,25(OH)2D3 on PTH levels and bone histology in dogs with chronic uremia Kidney Int 26 1984 791 797
87. W.E. Rutherford, K. Hruska, and J. Blondin The effect of 5,6-trans vitamin D3 on calcium absorption in chronic renal disease J Clin Endocrinol Metab 40 1975 13 18
88. L.R. Baker 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial Kidney Int 35 1989 661 669
89. J.W. Coburn Calcium-sensing receptor and calcimimetic agents Kidney Int Suppl 73 1999 S52 S58
90. W.G. Goodman A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism Kidney Int 58 2000 436 445
91. J.M. Frazao, P. Martins, and J.W. Coburn The calcimimetic agents: perspectives for treatment Kidney Int Suppl 80 2002 149 154
92. F. Llach, and M. Yudd Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism Am J Kidney Dis 38 5 Suppl 5 2001 S45 S50
93. O. Ifudu Care of patients undergoing hemodialysis N Engl J Med 339 1998 1054 1062
94. M. Teng Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy N Engl J Med 349 2003 446 456
95. C. Rigatto Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease J Am Soc Nephrol 13 2002 1084 1090
96. C. Rigatto Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia J Am Soc Nephrol 14 2003 462 468
97. R.N. Foley Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease J Am Soc Nephrol 11 2000 912 916
98. R.J. Middleton, P.S. Parfrey, and R.N. Foley Left ventricular hypertrophy in the renal patient J Am Soc Nephrol 12 2001 1079 1084
99. P.S. Parfrey Outcome and risk factors of ischemic heart disease in chronic uremia Kidney Int 49 1996 1428 1434
100. R.N. Foley The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease Am J Kidney Dis 28 1996 53 61
101. M.J. Sarnak Cardiovascular disease risk factors in chronic renal insufficiency Clin Nephrol 57 2002 327 335
102. A.S. Levey Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease Am J Kidney Dis 32 1998 853 906
103. G. Schillaci, G. Reboldi, and P. Verdecchia High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension Arch Intern Med 161 2001 886 891
104. J.T. Kielstein Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease J Am Soc Nephrol 13 2002 170 176
105. C. Zoccali Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study Lancet 358 2001 2113 2117